BioSpace News Archive

NS Pharma, Inc. announced today that the European Commission (EC) has granted Orphan Drug Designation to NS-018 (ilginatinib) an oral, selective JAK2 inhibitor which is being investigated for the treatment of myelofibrosis (MF).

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has received Institutional Review Board (IRB) approval for its landmark Phase 1b/2a proof-of-concept clinical trial protocol of its proprietary lead compound, NVG-291, in individuals with spinal cord injury (SCI).

Nephron 503B Outsourcing Facility, a division of Nephron Pharmaceuticals Corporation, is focused on resolving drug shortage concerns with the production of 0.5% Albuterol 5 mL, del Nido Cardioplegia, Lidocaine 1% and Succinylcholine products.

Hydromer, Inc. (OTC: HYDI) today announced the resignation of all its board of directors. There were no disagreements between the Company and the board of directors. The company has swiftly acted to ensure continuity and has appointed new members to its board of directors.

EmitBio Inc. is excited to announce its participation in the World Congress on Infectious Diseases, scheduled to take place from October 23 to 25, 2023 in Boston, Massachusetts.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced a key opinion leader roundtable discussion to be held on Friday, August 11, 2023, 8:00 a.m. – 9:00 a.m. ET to discuss the latest data from the ReSPECT-LM clinical trial of rhenium (186Re) obisbemeda that will be presented at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference on August 10, 2023.

Medtronic plc, a global leader in healthcare technology, announced that it will report financial results for its first quarter of fiscal year 2024 on Tuesday, August 22, 2023.

Applied BioMath announced they have been awarded a grant to develop a simulation platform to facilitate the prediction of optimal dose, therapeutic window, and best dosing strategy of Immunocytokines.

XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it submitted for publication its retrospective cardiomyopathy study to a leading stem cell journal.